HTEC Research: Only One in Three Healthcare Organizations is Ready to Scale AI
28.4.2026 15:22:00 CEST | Business Wire | Press Release
AI is already embedded across healthcare and life sciences. Most organizations are deploying it, and confidence in its potential is high. Yet for many, the real challenge is only just beginning.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260428872907/en/
HTEC, a global AI‑first provider of software and hardware design and engineering services, today released new research based on a global survey of 253 C-level HLS executives across the United States, United Kingdom, Germany, Spain, Saudi Arabia, and the UAE. AI is already embedded across healthcare and life sciences. Most organizations are deploying AI, and confidence in its potential is high. Yet for many, the real challenge is only just beginning.
HTEC, a global AI‑first provider of software and hardware design and engineering services, today released new research based on a global survey of 253 C-level HLS executives across the United States, United Kingdom, Germany, Spain, Saudi Arabia, and the UAE. The data suggests that AI progress in healthcare is becoming uneven—strong in pockets of innovation, but difficult to extend across the full complexity of care delivery and regulated operations.
“Real value emerges only when technology is thoughtfully embedded into clinicians’ everyday workflows, aligned with how care is actually delivered,” said Alfred Olivares, Managing Partner, Healthcare & Life Sciences at HTEC. “AI must complement clinical expertise—not disrupt it—if it is to deliver meaningful impact.”
AI Widespread, Scale Elusive
AI is now firmly on the strategic agenda across healthcare and life sciences. More than half of organizations (52.2%) report that AI is already embedded across multiple functions, and virtually all leaders consider it a priority.
Despite widespread adoption, scaling AI across clinical, operational, and R&D environments remains difficult—slowed by fragmented systems, capability gaps, and the need to balance innovation with safety, compliance, and trust.
Integration and Execution Alignment are the Biggest Barriers
The research identifies system integration and executive alignment as the primary obstacles to scaling AI in healthcare.
These challenges are amplified by:
- Fragmented clinical and enterprise systems
- Strict regulatory and compliance requirements
- Highly distributed ecosystems involving providers, patients, payors, and regulators
While 85.8% of leaders report strong or full alignment at a strategic level, 42.3% still cite lack of alignment as a barrier, highlighting a critical gap between intent and execution.
In practice, organizations often agree that AI matters, but diverge on how to prioritize use cases, allocate investment, and operationalize it safely at scale.
Edge AI Emerges as a Strategic Priority
Edge AI plays a uniquely strategic role in healthcare and life sciences. Nearly all leaders report familiarity with edge AI, and 97.9% express confidence in their ability to deploy it.
Notably, most organizations are adopting a hybrid edge-to-cloud approach—combining partnerships (61.7%), in-house development (53.6%), and third-party platforms (53.2%) to connect real-time data from devices and care settings with centralized clinical, research, and analytics systems.
This reflects the growing importance of distributed care models, connected medical devices, and the need to process sensitive data closer to the point of care.
Capability Gaps are Slowing Progress and Increasing Costs
Despite strong adoption, nearly all organizations (93.7%) report technical skill gaps that are directly impacting their ability to scale AI. The most critical gaps center around cybersecurity and data privacy, AI/ML expertise, and DevOps and automation. These constraints are already translating into measurable business impact, with 51.5% of organizations reporting higher costs, 41.4% experiencing reduced innovation, and 36.7% facing slower time to market.
Only One in Three Organizations Ready to Scale AI
Despite strong adoption and confidence in emerging technologies like edge AI, only about a third of healthcare organizations believe they can scale AI rapidly.
At the same time, leaders estimate that failing to act on AI and edge opportunities would set them back by 1.65 years on average, underscoring how narrow the competitive window has become.
This creates a clear inflection point: organizations must move beyond experimentation and isolated use cases toward coordinated, enterprise-wide execution.
The Next Phase of Healthcare AI
Healthcare and life sciences have already demonstrated strong momentum in AI adoption. But the next phase will not be defined by how widely AI is used, but how effectively it is operationalized and blended with the current clinician workflows.
The organizations that move ahead will be those that:
- Build governed, reusable data foundations
- Align leadership at both strategic and execution levels
- Invest in workforce enablement alongside technology
- Integrate AI directly into clinical and operational workflows
“The competitive window is narrow, but it is not yet closed,” said Stefan Mrsic, Managing Partner, Healthcare & Life Sciences at HTEC. “The next phase will be defined by the ability to combine innovation with safety, explainability, and human judgment.”
The State of AI in the Healthcare and Life Sciences Industry 2025-2026 is now available for download.
About the Research
The report was commissioned by HTEC and conducted by Censuswide. It includes the insights from 1,529 C-suite leaders across the USA, UK, Germany, Spain, Saudi Arabia, and the UAE, spanning CEOs, CIOs, CTOs, CDOs, CFOs, COOs, CPOs, and CSOs across industries, including financial services, healthcare, automotive, telecommunications, retail, and semiconductors.
About HTEC
HTEC Group Inc. is a global AI-first provider of strategic, software and hardware embedded design and engineering services, specializing in Advanced Technologies, Financial Services, MedTech, Automotive, Telco, and Enterprise Software & Platforms. HTEC has a proven track record of helping Fortune 500 and hyper-growth companies solve complex engineering challenges, drive efficiency, reduce risks, and accelerate time to market. HTEC prides itself on attracting top talent and has strategically chosen the locations of its 20+ excellence centers to enable this.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260428872907/en/
Contacts
Media Contact:
media@htecgroup.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press Release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press Release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press Release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 14:00:00 CEST | Press Release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press Release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom